{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055942","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.362625+00:00","generated_at":"2026-06-28T09:58:16.900558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cogent Biosciences Q3 net loss $19.1M; initiates SUMMIT Phase 2, cash $202.9M","bullets":["Net loss of $19.1M in Q3 2021 vs $50.0M in Q3 2020 (prior included $46.9M asset acquisition charge).","Cash and equivalents $202.9M; expected to fund operations into 2024.","Initiated SUMMIT Phase 2 trial for bezuclastinib in nonadvanced systemic mastocytosis.","APEX Phase 2 trial for AdvSM on track for preliminary data readout H1 2022.","Appointed Dana Martin as Chief Patient Officer and Courtney Watson as VP Clinical Development."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055942","json":"https://secwatch.observer/filing/0001564590-21-055942.json","markdown":"https://secwatch.observer/filing/0001564590-21-055942.md","text":"https://secwatch.observer/filing/0001564590-21-055942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000156459021055942/0001564590-21-055942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000156459021055942/cogt-8k_20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:58:16.900558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}